EpiVario is a preclinical pharmaceutical company developing novel compounds to treat memory-related psychiatric disorders at the source of the disease.

Co-Founded by epigeneticists at the University of Pennsylvania, who discovered new mode of action for memory formation and re-consolidation.

Through this discovery, EpiVario is developing new small molecule compounds for the goal for reducing or preventing the pathogenesis of psychiatric diseases: post-traumatic stress disorder (PTSD) and substance abuse disorders